Addressing dementia risk likely requires simultaneous support of metabolism, mitochondria, vascular health, and cellular health with GLP-1s providing a powerful foundation upon which multi-modal brain health strategies can be built
Companies Sued For Ozempic or Other GLP-1 Injury Defendants named in GLP-1 injury lawsuits have included manufacturers, sellers and/or distributors of various GLP-1 receptor agonist medications, including: Novo Nordisk (Ozempic, Rybelsus, Wegovy, Saxenda) Eli Lilly (Mounjaro, Zepbound, Trulicity) Other GLP-1 injury defendants Ozempic GLP-1 Lawsuit & Settlement Updates Recent updates about Ozempic lawsuits and settlements include: July 2026: GLP-1 lawsuits remain active in federal and state courts
Over 72 weeks, tirzepatide produced notably greater weight loss across every metric the researchers measured
Excitatory and inhibitory processes acting upon individual Purkinje cells of the cerebellum in cats